Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
A small biotech firm is the second company to start human tests of embryonic stem-cell therapy.
The findings cast doubt on a promising alternative to the use of embryonic stem cells in medicine.
Some scientists are reluctant to enter the field, and some consider leaving it altogether, because of the uncertainty of government regulations.
Replacing certain cells in the retina could slow visual impairment for people with macular degeneration.
Once again, federal funding restrictions cast uncertainty over the field.
Human embryonic stem cells can be coaxed into three-dimensional structures of retinal cells.